Researchers at IDIBAPS and the Imperial College London publish a study in which they have discovered that RNA sequences that do not encode for proteins play a key role in the expression of certain genes in the beta cells of the pancreas. These genes are known to be involved in the development of different forms of diabetes. Dr. Jorge Ferrer, head of the team Genomic Programming of Beta Cells and Diabetes at IDIBAPS and at the Imperial College London and researcher at the Networked Biomedical Research Center for Diabetes and Associetaed Metabolic Diseases (CIBERDEM), coordinates this study published in the journal Cell Metabolism. Read the rest of this entry »
Hospital Clinic-IDIBAPS coordinates a European project to obtain a functional cure for HIV with immunotherapy
The IDIBAPS and the Hospital Clínic of Barcelona lead a European project aimed at changing the current paradigm of HIV treatment by obtaining a functional cure. The main goal is to control HIV replication over long periods of time or throughout life without antiretroviral treatment. Dr. Felipe Garcia, senior consultant of the Infectious Diseases Department at Hospital Clínic and researcher of the IDIBAPS team on Infectious Diseases and AIDS, coordinates this study called HIVACAR. This initiative is part of the European research and innovation framework program Horizon 2020, has a total budget of 6.7 million euro and 14 institutions will participate, among clinical and research centers and European companies. In Spain, the other participating institutions are the IrsiCaixa AIDS Research Institute, the National Center for Biotechnology (CNB-CSIC) and the Faculty of Economics and Business Sciences of the Complutense University of Madrid (UCM). Read the rest of this entry »
Drs. Francesc Artigas and Analía Bortolozzi, researchers of the team of Neuropharmacology and Experimental Neuropathology in the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the IIBB-CSIC, have just published a “Hot Topic” article in the first issue of 2017 in the journal Neuropsychopharmacology, one of the most prestigious in the field of Psychiatry and Neuropharmacology. This section of the journal, published at the beginning of each year, collects significant advances recently produced in the field.
The article briefly reviews the advances made by the group in the development of new experimental strategies for a more rapid and effective treatment of depression through the use of interfering RNA molecules conjugated to serotonin reuptake inhibitors. These advances were published in the journals Molecular Psychiatry and Traslational Psychiatry and show that these conjugates produce an antidepressant effect faster than the conventional drugs in experimental models, which means a remarkable advance with a possible therapeutic application.
Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder
Artigas F, Bortolozzi A.
Neuropsychopharmacology. 2017 Jan;42(1):371. doi: 10.1038/npp.2016.182.
Scientists at Salk Institute have made breakthroughs in the integration of human cells into embryos of a different species
Scientists at Salk Institute for Biological Studies in California have made breakthroughs on multiple fronts in the race to integrate pluripotent stem cells from one species into the early-stage development of another. This will allow to study the embryonic development of an organism, diseases, test new therapeutic drugs and the possibly grow transplantable. Dr. Juan Carlos Izpisúa, professor in Salk’s Gene Expression Laboratory, leads this study published in today’s issue of the journal Cell. Dr. Josep M. Campistol, CEO and nephrologist in Hospital Clínic and researcher in IDIBAPS, and scientists from the Catholic University of Murcia (UCAM), the Pedro Guillén Foundation, the CEMTRO Clinic in Madrid and the University of Murcia, have also participated.
Dr. Josep Dalmau, ICREA Professor of IDIBAPS, where he leads the Group Pathogenesis of autoimmune neuronal disorders, and consultant of the Neurology Department of Hospital Clínic, has been named Chair of the Autoimmune Neurology Section in the American Academy of Neurology (AAN). It is a newly created section that wants to differentiate itself from the classic concept of neuroimmunology, more linked to other types of diseases such as Multiple Sclerosis. The founders of the section are Drs. Sean Pittock, of the Mayo Clinic, and Jeffrey Gelfand, of the University of California San Francisco (UCSF). Read the rest of this entry »
A treatment increases survival by 50% in mice with Niemann-Pick type C, a rare disease that affects brain and liver
Researchers from the IIBB-CSIC and the IDIBAPS publish an article in the journal Redox Biology in which they propose an alternative treatment for Niemann-Pick disease type C, a rare lysosomal pathology that causes neurodegeneration and impaired liver function. With a compound that crosses the blood-brain barrier, it is possible to increase the survival of the mice by 50% and to improve the neurological and motor problems related to the disease. Dr. José C. Fernández-Checa, head of the IDIBAPS team on Mitochondrial regulation of cell death and steatohepatitis, and Dr. Carmen García-Ruiz, from the same team, are the coordinators of the study, which has been carried out in collaboration with researchers from France and Chile. The first author of the study is Sandra Torres, predoctoral researcher in Dr. Fernández-Checa’s lab.